Levetiracetam Stragen (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which plays a crucial role in the regulation of neurotransmitter release. This binding modulates calcium‑dependent exocytosis, leading to reduced excitatory neurotransmission and stabilization of neuronal firing, thereby decreasing the likelihood of seizure propagation.

The appropriate dose of Levetiracetam Stragen is individualized by the prescribing clinician based on factors such as the patient’s age, weight, renal function, severity of seizures, and prior response to therapy. No fixed regimen is provided here; the prescriber will set the dosage and infusion rate according to clinical judgment.

Safety data for levetiracetam during pregnancy and lactation are limited, and the product carries an unknown pregnancy category. Clinicians should weigh the potential benefits against possible risks, and consider alternative therapies when appropriate. Breastfeeding mothers should consult their healthcare provider before using the medication.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Levetiracetam Stragen. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Levetiracetam offers a favorable pharmacokinetic profile with minimal protein binding and few drug‑enzyme interactions, distinguishing it from older agents such as valproate or carbamazepine, which often require therapeutic drug monitoring and have broader interaction potentials. Its rapid intravenous formulation provides swift seizure control, whereas some alternatives may be limited to oral administration.

Levetiracetam Stragen should be stored refrigerated at 2‑8 °C. The solution must be kept in its original container, protected from light, and should never be frozen or shaken vigorously. If the product must be transported, maintain the cold‑chain conditions throughout to preserve stability.

The medication is supplied as an intravenous solution and is administered by slow infusion into a vein, typically over 15 minutes or as directed by the treating physician. Administration should be performed by qualified healthcare personnel in a setting equipped for intravenous therapy and patient monitoring.

Serious adverse events include severe allergic reactions such as anaphylaxis, significant mood or behavioral changes (including depression, suicidal ideation, or aggression), and hematologic abnormalities like thrombocytopenia or neutropenia. Patients should be monitored closely for these signs, and any concerning symptoms should prompt immediate medical evaluation.

Levetiracetam Stragen is contraindicated in individuals with known hypersensitivity to levetiracetam or any component of the formulation. Caution is also advised for patients with severe renal impairment where dosing adjustments may be required, and for those with a history of serious psychiatric disorders without appropriate monitoring.